iuvo BioScience, a specialty PRO (Partner Research Organization) providing preclinical and clinical development services, lab services, and scientific consulting, has acquired Promedica International, a California Corp. (PMI), a specialty ophthalmology-focused clinical CRO. The combined organization will support all aspects of ophthalmic clinical research, from front of the eye to back of the eye, leveraging an even larger team of experts in ophthalmology.
 
As part of the transaction, iuvo has appointed Shannon Stoddard as President, Clinical Research for the combined clinical research business. Shannon will also serve on the Board of Directors of iuvo BioScience.
 
Ben Burton, President and CEO of iuvo, said, “I have known Shannon and the PMI team for several years, and have great respect for their expertise and industry-leading position in the marketplace. Shannon’s employee-centric and Sponsor-dedicated approach is a perfect strategic and cultural fit with the iuvo team. Under Shannon’s leadership, we will remain focused on what has made each business successful: excellent client service, outstanding therapeutic expertise and an experienced team dedicated to collaborating with each other and the Sponsor.”
 
Through the combination of the two companies, iuvo and PMI will be a niched ophthalmology service provider able to support customers from the early preclinical and lab stages through all phases of clinical development.
 
Shannon Stoddard, President and Owner of PMI, said, “The PMI team is thrilled to join iuvo BioScience. Our company was formed nearly forty years ago with the sole focus of providing differentiated clinical research services to medical device and pharmaceutical companies across the globe. We have had an impressive track record of Sponsor approvals and look forward to continuing this trend as part of iuvo.”